🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Piramal Pharma Limited PPLPHARMA NIFTY_SMALLNSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.piramalpharma.com
Company Profile ↓
₹173.85
-13.30% 1Y
Mkt Cap₹23,108.98 Cr
P/E-70.67
P/B2.68
Div. Yield0.08%
52W High₹216.88
52W Low₹133.27
Book Value₹61.41
EPS (TTM)₹-2.46

Company Overview

Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing; offers inhalation anesthetics, intrathecal therapy for spasticity management, injectable pain management drugs, and other generic and speciality products; and analgesics, skin care, vitamin and mineral supplement, kids' wellness, digestives, and women's health, as well as geriatric care. The company was incorporated in 2020 and is based in Mumbai, India.

Why Investors Should Care

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹8,758.82 Cr (-3.3% YoY); net profit ₹-325.94 Cr.
  • Trailing 12 Months Year-on-year growth — revenue -3.3%, earnings -457.7%.
  • 5-Year Trend Long-term compounding — revenue CAGR 7.6%, profit CAGR -24.9%.

Growth & Price Performance

Compounded Sales Growth

5 Years:7.59%
1 Year:-3.33%

Compounded Profit Growth

5 Years:-24.93%
1 Year:-457.66%

Stock Price Performance

1 Year:-13.30%
6 Months:+3.65%
3 Months:+16.80%
1 Month:+6.22%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 49% of range
₹133.27 ₹216.88
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • Golden Cross2d ago
  • RSI (14)54.52 · Neutral
Price Performance
1M+6.22%
3M+16.80%
6M+3.65%
1Y-13.30%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Earnings shrank at -24.9% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-70.67
Industry PE
39.97
Forward P/E
41.29
PEG Ratio
-
Book Value
₹61.41
Price to Book
2.68
P/S
2.60
EV/EBITDA
32.80
Dividend Yield
0.08%

Growth (CAGR)

Revenue 5Y
7.59%
Profit 5Y
-24.93%
Revenue (YoY)
-3.33%
Earnings (YoY)
-457.66%

Profitability & Returns

ROCE
1.23%
ROE
-3.99%
ROA
-1.81%
Profit Margin
-3.72%
Op Margin
1.77%
Gross Margin
59.09%
EPS (Latest Qtr)
₹-0.07
EPS (TTM)
₹-2.46

Balance Sheet & Liquidity

Debt/Equity
0.70
Quick Ratio
0.87
Current Ratio
1.51
Debt
₹5,674.58 Cr
Total Assets
₹17,965.04 Cr
Current Assets
₹7,191.66 Cr
Working Capital
₹2,433.38 Cr

Ownership

Promoter Holding
54.45%
Chg in Prom Hold
19.60%
FII / Inst Holding
21.38%
Chg in FII Hold
0.02%

Financial Snapshot

Enterprise Value
₹23,108.98 Cr
Total Revenue (TTM)
₹8,758.82 Cr
EBITDA
₹993.53 Cr
Free Cash Flow
₹762.57 Cr
Operating Cash Flow
₹1,652.59 Cr
Shares Outstanding
₹132.92 Cr
Gross Margin
59.09%
Payout Ratio
15.07%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 PPLPHARMA Piramal Pharma Limited NIFTY_SMALLNSEPHARMA 173.85 -70.67 ₹23,108.98 Cr 0.08% 1.23% -3.99% 7.59% -24.93%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 2,163.58 Cr1,748.85 Cr1,911.38 Cr1,958.57 Cr2,552.36 Cr1,951.14 Cr2,241.75 Cr2,204.22 Cr2,754.07 Cr1,933.71 Cr2,043.72 Cr2,139.87 Cr2,751.77 Cr
Cost of Revenue -------805.83 Cr954.98 Cr694.05 Cr-786.31 Cr1,055.67 Cr
Gross Profit -------1,398.39 Cr1,799.09 Cr1,239.66 Cr-1,353.56 Cr1,696.10 Cr
Operating Expenses 1,812.31 Cr1,616.53 Cr1,645.74 Cr1,690.20 Cr2,022.43 Cr1,746.65 Cr1,900.14 Cr1,257.46 Cr1,480.86 Cr1,330.24 Cr1,885.03 Cr1,370.57 Cr1,453.97 Cr
Operating Income 166.86 Cr-41.29 Cr81.13 Cr82.05 Cr333.80 Cr19.94 Cr149.39 Cr140.93 Cr318.23 Cr-90.58 Cr-44.15 Cr-17.01 Cr242.13 Cr
EBITDA 351.27 Cr132.32 Cr265.64 Cr268.37 Cr529.93 Cr204.49 Cr341.61 Cr366.92 Cr619.24 Cr204.41 Cr158.69 Cr208.12 Cr344.37 Cr
Interest Expense 104.25 Cr118.52 Cr109.87 Cr105.88 Cr114.22 Cr106.96 Cr107.64 Cr103.31 Cr103.68 Cr86.15 Cr82.42 Cr89.24 Cr82.99 Cr
Pretax Income 94.89 Cr-107.11 Cr39.56 Cr19.36 Cr227.48 Cr-45.08 Cr120.12 Cr66.80 Cr272.80 Cr-79.02 Cr-46.18 Cr-93.86 Cr43.00 Cr
Tax Provision 44.78 Cr8.53 Cr34.54 Cr9.25 Cr126.21 Cr-43.56 Cr97.53 Cr63.12 Cr119.30 Cr2.68 Cr-53.04 Cr42.33 Cr51.83 Cr
Net Income 50.11 Cr-98.58 Cr5.02 Cr10.11 Cr101.27 Cr-88.64 Cr22.59 Cr3.68 Cr153.50 Cr-81.70 Cr-99.22 Cr-136.19 Cr-8.82 Cr
Diluted EPS 0.38-0.750.040.080.77-0.670.170.031.16-0.62-0.75-1.03-0.07

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 6,315.00 Cr-7,032.41 Cr8,106.41 Cr9,061.00 Cr8,758.82 Cr
Cost of Revenue --3,000.18 Cr3,258.76 Cr3,572.13 Cr3,583.63 Cr
Gross Profit --4,032.23 Cr4,847.65 Cr5,488.87 Cr5,175.19 Cr
Operating Expenses 4,887.00 Cr-4,080.20 Cr4,385.62 Cr4,810.22 Cr5,020.28 Cr
Operating Income 883.00 Cr--47.97 Cr462.03 Cr678.65 Cr154.91 Cr
EBITDA 1,428.00 Cr-894.25 Cr1,366.81 Cr1,648.91 Cr993.53 Cr
Interest Expense 163.00 Cr-337.71 Cr446.95 Cr417.93 Cr338.35 Cr
Pretax Income 949.00 Cr--120.15 Cr179.29 Cr414.64 Cr-176.06 Cr
Tax Provision 113.88 Cr-66.31 Cr161.47 Cr323.51 Cr149.88 Cr
Net Income 835.00 Cr--186.46 Cr17.82 Cr91.13 Cr-325.94 Cr
Diluted EPS ---1.540.140.69-2.46

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 10,677.00 Cr-14,522.56 Cr15,311.81 Cr15,677.59 Cr17,965.04 Cr
Current Assets --4,835.48 Cr5,464.47 Cr5,796.99 Cr7,191.66 Cr
Cash & Equivalents --195.59 Cr356.82 Cr368.98 Cr1,199.88 Cr
Inventory --1,681.37 Cr2,175.88 Cr2,312.70 Cr3,064.44 Cr
Receivables --1,799.34 Cr2,134.43 Cr2,349.52 Cr2,157.67 Cr
Total Liabilities --7,749.06 Cr7,400.44 Cr7,552.12 Cr9,802.42 Cr
Current Liabilities --3,843.05 Cr4,369.30 Cr3,766.27 Cr4,758.28 Cr
Long Term Debt --3,383.54 Cr2,483.75 Cr3,214.07 Cr4,299.97 Cr
Total Debt 3,025.00 Cr-5,637.08 Cr4,710.16 Cr4,856.47 Cr5,674.58 Cr
Total Equity 5,605.00 Cr-6,773.50 Cr7,911.34 Cr8,125.41 Cr8,162.58 Cr
Shares Outstanding --122.19 Cr132.29 Cr132.57 Cr132.92 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 598.00 Cr-483.89 Cr1,004.54 Cr892.30 Cr1,652.59 Cr
Investing Cash Flow -4,464.00 Cr--1,338.78 Cr-434.01 Cr-477.46 Cr-826.03 Cr
Financing Cash Flow 3,977.00 Cr-817.79 Cr-422.34 Cr-440.83 Cr-38.98 Cr
Capital Expenditure -603.00 Cr--964.75 Cr-712.04 Cr-664.38 Cr-890.02 Cr
Free Cash Flow -5.00 Cr--480.86 Cr292.50 Cr227.92 Cr762.57 Cr
Net Change in Cash 110.00 Cr--37.10 Cr148.19 Cr-25.99 Cr787.58 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --57.3%59.8%60.6%59.1%
Operating Margin % 14.0%--0.7%5.7%7.5%1.8%
Net Margin % 13.2%--2.7%0.2%1.0%-3.7%
ROE % 14.9%--2.8%0.2%1.1%-4.0%
ROCE % ---0.4%4.2%5.7%1.2%

Shareholding Pattern

Insiders
54.45%
Institutions
21.38%
Public Float
46.94%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for PPLPHARMA

Google News hu, 25 Jun 2026

PPLPHARMA Forecast — Price Target — Prediction for 2027 - TradingView

<a href="https://news.google.com/rss/articles/CBMifEFVX3lxTE8xT3dKM2h5Uk5pWURPM1F2R2FyZE14MloyQXNFYlJhX2c0RlUyWjh5S0pkMkxUTjd1SFJQTU9PSmhsNk5YcE42azJ4MzFGRnRvLWtnWmllUV90R3FWZFVPNHhwMWZxd3Zydl9SdEtuNWY5aXJreXM5VWRPX2Y?oc=5" target="_blank">…

Google News Sat, 31 Jan 2026

Piramal Pharma Limited (NSE:PPLPHARMA) Just Reported Earnings, And Analysts Cut Their Target Price - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi7gFBVV95cUxNbWFkeS1NeHNXSGd6NjZxcFdZVFRiRHNJME42b2gzbU02dEpsZVo4cFRoSnNTQWE5Uk5TalN1RkNBOXFYY2lrSlhxelZKNndqV3FxOVBRYXhERld3LUV6NmJYVnJ1aDVYcENXcjMyd3JTYmM1VXlsMkp0bWFaVFlkbjA4QVB4cGdEYzJ4ZG…

Google News Mon, 06 Jul 2026

Stocks to buy: Piramal Pharma, HSCL among 3 top bets by Choice Broking - Business Standard

<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxPT1UxVjRHbEdYa3ZTTFl0TXhjTGVlZDdqWW9RYnJneHN5dnpWYldOeVBUWkVWaGtXazk5Si1PUjhlSjlHaGxHdFh6YTlob3lvQlNGckxsUkR3RzJadUhOQzRyQnh2V1ltWGNLUUhVaUVXRklYUE9OQmlFWC1jYUM4TmlPYWJ1OWpxVm9OVW…

Google News ue, 23 Jun 2026

Piramal Pharma Share Price Spikes Over 10% — What Is Driving The Rally? - NDTV Profit

<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxQUE10LU5FNmhpNzZMb19XdUllSlNYMWVpN3p2UHNsV2psbTFweDlEYjZzMmd1bHVvc25yMmdlZG9IaDNBX1FPbFJYOUJ0RnUyM2k1Vm1zYko3dzBxUkRoUHQ3NktsQnNyYUlFdTlmZVNSUDB5bVJDYkxVeVhKeXljcDFmeEsyMzQ0ckZrN1…

Google News hu, 15 Jan 2026

Piramal Pharma (NSE:PPLPHARMA) Takes On Some Risk With Its Use Of Debt - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxQczYxUlRCNjBSNkJEQVhocFhtZjlueC1KMG84UGR6QzNyU1hTT01Ubk5OMEduNGxTTW9tWXVpbWwydG93dXpqaEgxTDdUUW4tNXIxbUppZE9sN3ZXblNSM0VzOXFuSmF0dEViaVdVczJ2WXhzeTctOHVJYkxPRE5WR3g3Z1VGWHI4UnAyS2…

Google News Sat, 03 Jan 2026

Piramal Pharma Ltd. Share Price Today - Piramal Pharma Ltd. Stock Price Live NSE/BSE - CNBC TV18

<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxOUXVHS3NYLWU4b2ZzYU1XMlNlbFpmd0xfMHFfU1hBRDFsVjZObjFUb0xCc0wzejRTd2RoSV84M1RxLVFpYlRVcXJRMEo5LTRMTUo1dnhTOFd2anJsZDFGZVFXdGQ5UHoxdHNOUWR6SXpBUHZ2djJfZkd1bmVya0Y5Nw?oc=5" target="_…

PPLPHARMA — Frequently Asked Questions

What is the current share price of Piramal Pharma Limited (PPLPHARMA)?

As of 2026-07-15 09:52 IST, Piramal Pharma Limited (PPLPHARMA) trades at ₹173.85 on NSE. Its 52-week range is ₹133.27 to ₹216.88.

What is the market capitalisation of PPLPHARMA?

Piramal Pharma Limited (PPLPHARMA) has a market capitalisation of ₹23,108.98 Cr on NSE.

What is the P/E ratio of PPLPHARMA?

PPLPHARMA trades at a trailing price-to-earnings (P/E) ratio of -70.67. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 2.68.

Does PPLPHARMA pay a dividend?

Piramal Pharma Limited (PPLPHARMA) currently offers a dividend yield of 0.08%.

What is the return on equity (ROE) of PPLPHARMA?

PPLPHARMA has a return on equity (ROE) of -3.99%. Its return on capital employed (ROCE) is 1.23%.

Is PPLPHARMA a good stock to buy?

This page provides a data-driven analysis of Piramal Pharma Limited (PPLPHARMA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space